Optune Lua For Malignant Pleural Mesothelioma
Posted Date: Feb 25, 2022
- Investigator: Emily Daugherty
- Specialties: Cancer, Lung Cancer, Oncology, Pulmonary Diseases, Radiation Oncology
- Type of Study: Device
Certified user delivery of Optune Lua for use concurrent with pemetrexed plus platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced or metastatic malignant pleural mesothelioma (MPM).
Criteria:
Patients Over 18 Years Old With Unresectable, Locally Advanced Or Metastatic Malignant Pleural Mesothelioma (Mpm)
Keywords:
Tumor-Treating Fields, Mesothelioma
For More Information:
Dr. Emily Daugherty, Md
NULL
daugheec@ucmail.uc.edu